Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman

Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. 


Michael Hofman, MBBS (Hons), FRACP, FAANMS, Professor, Molecular Imaging, The University of Melbourne, Nuclear Medicine Physician in the Centre for Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, Australia 

Alicia Morgans, MD, MPH


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.